Home > Boards > US OTC > Biotechs > Emmaus Life Sciences (EMMA)

Net revenues of EMI for the 2019 second

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
namah sivaya Member Profile
 
Followed By 11
Posts 1,636
Boards Moderated 0
Alias Born 01/07/15
160x600 placeholder
namah sivaya   Monday, 08/12/19 08:06:06 AM
Re: None
Post # of 10 
Net revenues of EMI for the 2019 second quarter increased 128% to $5.9 million, up from $2.6 million for the same period last year, and 11% from the first quarter of 2019. The increase was driven by the continuing roll-out and market acceptance of Endari®, the first treatment approved by the FDA for sickle cell disease in nearly 20 years.

https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-sharply-improved-2019-second-quarter-financial-results-300899734.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences